Mutations in the genes that code for proteins in this pathway have been linked to various types of cancer (i.E., ras-pancreatic, braf-colorectal, mek-melanoma, egfr-lung). If you were developing a new cancer drug, what would be an appropriate target protein for the new drug therapy?

The given proteins, such as EGFR (epidermal growth factor receptor), ras, MEK, and b-raf, are in involved in pathway that stimulates and control cell growth. The epidermal growth factor binds with EGFR that transmits the downstream signals with the help of various cytosolic proteins, as Ras to raf, and raf to MEK. These proteins activate signalling pathways that induce growth and division of the cell, thus, any gain of function mutation in these proteins lead to uncontrolled cell growth and debeloment of cancer.

If a new cancer drug is developed to target this pathway, it should be able to bind with EGFR instead of its ligand EGF. These drugs include monoclonal antibodies against EGFR that block the EGFR-Ras-raf-MEK pathway by inhibiting signal transduction from membrane receptor EGFR to cytosolic proteins and thus, control cell division and prevent tumor formation.

kasliwalalvi24 kasliwalalvi24 · Answer 2 · 2021-10-23T12:16:37+02:00

Mutations are the changes in the genetic sequences of DNA. The mutations in the genes coding for proteins have been reported to be linked to various types of cancer. If new drug is developed it should be able to target EGFR instead of EGF.

The given proteins Epidermal growth factor receptor (EGRF), ras, and MEK are in the pathway that stimulates the growth of the cell. The EGFR binds with epidermal growth factor, which helps in the transmission of downstream signals. The proteins involved in the signalling are MEK, Ras to raf, and cytosolic proteins. The proteins activate the signalling pathways that are involved in the growth and division of the cells. The mutation in these proteins can lead to abnormal growth of cells.

The new cancer drug developed should be able to target the pathway of EGFR. These drugs consists of monoclonal antibodies against EGFR. The antibodies will block the pathway of EGFR-Ras-raf-MEK by inhibiting the signal transduction.

Therefore, controlled cell division and prevention of tumor can be done by blocking EGRF pathway.

To know more about drug therapy, refer to the following link:

https://brainly.com/question/13787213?referrer=searchResults